ORIC Pharmaceuticals（纳斯达克代码：ORIC）股价下跌 6.8% - 现在是卖出的时候吗？

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report)'s share price fell 6.8% on Wednesday . The stock traded as low as $10.97 and last traded at $11.2850. 592,162 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 1,798,275 shares. The stock had previously closed at $12.11.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Piper Sandler initiated coverage on Oric Pharmaceuticals in a research report on Wednesday, January 7th. They issued an "overweight" rating and a $22.00 price objective for the company. Wall Street Zen cut shares of Oric Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday, November 23rd. JPMorgan Chase & Co. boosted their price target on Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an "overweight" rating in a report on Tuesday, November 18th. Wells Fargo & Company upped their price target on Oric Pharmaceuticals from $19.00 to $25.00 and gave the company an "overweight" rating in a research report on Monday, December 8th. Finally, Oppenheimer lifted their price objective on Oric Pharmaceuticals from $12.00 to $15.00 and gave the stock an "outperform" rating in a research report on Friday, November 14th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $19.90.

Check Out Our Latest Stock Report on Oric Pharmaceuticals

Oric Pharmaceuticals Stock Down 6.1%

The business has a fifty day simple moving average of $10.10 and a 200-day simple moving average of $10.93. The firm has a market cap of $1.11 billion, a P/E ratio of -6.59 and a beta of 1.36.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.08. On average, sell-side analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Insider Transactions at Oric Pharmaceuticals

In other news, CEO Jacob Chacko sold 33,374 shares of Oric Pharmaceuticals stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $302,368.44. Following the completion of the transaction, the chief executive officer owned 581,711 shares of the company's stock, valued at $5,270,301.66. The trade was a 5.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Pratik S. Multani sold 10,720 shares of the firm's stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20. Following the sale, the insider owned 68,149 shares of the company's stock, valued at approximately $617,429.94. This represents a 13.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 54,814 shares of company stock valued at $496,615. Insiders own 5.55% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Oric Pharmaceuticals during the fourth quarter valued at $135,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Oric Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company's stock valued at $39,000 after purchasing an additional 977 shares during the last quarter. Tema Etfs LLC bought a new position in Oric Pharmaceuticals during the fourth quarter valued at approximately $228,000. Hennion & Walsh Asset Management Inc. boosted its holdings in Oric Pharmaceuticals by 15.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 170,072 shares of the company's stock worth $1,391,000 after purchasing an additional 23,024 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in Oric Pharmaceuticals by 127.6% in the 4th quarter. SG Americas Securities LLC now owns 41,016 shares of the company's stock worth $336,000 after purchasing an additional 22,993 shares during the period. Hedge funds and other institutional investors own 95.05% of the company's stock.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.

Read More

• Five stocks we like better than Oric Pharmaceuticals
• Your Signature Is Missing – Act Before It’s Too Late
• What Expenses Can Be Deducted From Capital Gains Tax?
• Do not delete, read immediately
• Refund From 1933: Trump’s Reset May Create Instant Wealth
• Buy This Stock at 9:30 AM on MONDAY!

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oric Pharmaceuticals Right Now?

Before you consider Oric Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.

While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here